Chai Discovery
Chai Discovery is pioneering frontier AI models to revolutionize drug discovery and therapeutic design. The company seeks an AI Research Scientist to conduct innovative research on computational modeling in biological applications, aiming to move beyond protein structure prediction into real-world therapeutic engineering.
Chai Discovery is a pioneering biotechnology company focused on leveraging artificial intelligence to enhance the design and engineering of biochemical molecules. Their technology aims to improve the processes of designing, predicting, and reprogramming molecular interactions, particularly in the field of antibody development. With the introduction of Chai-2, they are offering advanced solutions that enable zero-shot antibody design, showcasing their commitment to innovation in molecular design.
Chai infuses AI drug discovery efforts with $130M series B
Dec 15, 2025
Revolutionizing Antibody Design with AI: Why We’re Backing Chai Discovery
Aug 6, 2025
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development
1 month ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Chai Discovery.
Chai Discovery didn’t post a salary, so this is our estimate from similar listings.
This Startup Backed By OpenAI and the Jobs Family Is the Latest A.I. Drug Discovery Unicorn
Dec 15, 2025
Senior Machine Learning Scientist
Pfizer
Senior Scientist, AI Computational Structural Biology
Bristol Myers Squibb
Protein Bioinformatics - Postdoctoral Researcher
LLNL
Senior Research Scientist, Machine Learning (BioFM)
Deep Genomics
Senior Computational Biologist - AI/ML and Protein Structure
Talent
AI Scientist Intern
Xaira Therapeutics